Entered into a definitive merger agreement with Advaxis Inc. – transaction expected to close by end of Q1 2023, subject to approval by Ayala’s shareholders.
The new company will advance Ayala's gamma secretase inhibitors and Advaxis' prostate cancer candidate ADXS-504, but lung cancer drug ADXS-503 will be discontinued.
Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Ayala Pharmaceuticals (AYLA) and Adaxis (ADXS) to Merge streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.